VolitionRx Files 8-K/A Amendment

TL;DR

VOLITIONRX LTD filed an 8-K/A on Nov 10, 2025, amending a Nov 7, 2025 event related to a material agreement.

AI Summary

VolitionRx Limited filed an 8-K/A on November 10, 2025, to amend a previous filing. The amendment pertains to the entry into a material definitive agreement and includes financial statements and exhibits. The earliest event reported in this amendment was on November 7, 2025.

Why It Matters

This filing is an amendment to a previous report, indicating updates or corrections to material definitive agreements or financial disclosures made by VolitionRx Limited.

Risk Assessment

Risk Level: low — This is an amendment filing (8-K/A) which typically clarifies or corrects previous information rather than introducing new, significant risks.

Key Players & Entities

• VolitionRx Limited (company) — Registrant
• November 7, 2025 (date) — Earliest event reported
• November 10, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 001-36833 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
• $0.52 — ombined offering price to the public of $0.52 per share of Common Stock and accompany
• $0.01 — se one share of Common Stock, including $0.01 per common stock warrant, less an under

Filing Documents

• vnrx_8ka.htm (8-K/A) — 27KB
• vnrx_ex11.htm (EX-1.1) — 3KB
• vnrx_ex11img1.jpg (GRAPHIC) — 249KB
• vnrx_ex11img2.jpg (GRAPHIC) — 168KB
• vnrx_ex11img3.jpg (GRAPHIC) — 70KB
• 0001477932-25-008019.txt ( ) — 819KB
• vnrx-20251107.xsd (EX-101.SCH) — 5KB
• vnrx-20251107_lab.xml (EX-101.LAB) — 15KB
• vnrx-20251107_cal.xml (EX-101.CAL) — 1KB
• vnrx-20251107_pre.xml (EX-101.PRE) — 9KB
• vnrx-20251107_def.xml (EX-101.DEF) — 2KB
• vnrx_8ka_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on October 10, 2025, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with Newbridge Securities Corporation (the "Underwriter"), relating to an underwritten public offering of 11,550,000 shares (the "Closing Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,000 shares of Common Stock at a combined offering price to the public of $0.52 per share of Common Stock and accompanying common stock warrant to purchase one share of Common Stock, including $0.01 per common stock warrant, less an underwriting commission of 7.0% (the "Offering"). Pursuant to the terms of the Underwriting Agreement, the Company also granted the Underwriter a 30-day option (the "Over-Allotment Option") to purchase up to an additional 1,732,500 shares of Common Stock (the "Option Shares"), as well as accompanying common stock purchase warrants to purchase up to an aggregate of 1,732,500 shares of Common Stock (the "Option Warrants") at the same price per share and accompanying warrant. On November 7, 2025, the Company and the Underwriter entered into an amendment to the Underwriting Agreement (the "Amendment"), to modify the terms of the Over-Allotment Option. The Amendment permits the Underwriter, in its sole discretion, to exercise the Over-Allotment Option with respect to the Option Shares, the Option Warrants, or any combination thereof, rather than solely as a single, combined exercise for both. Concurrently with the execution of the Amendment, the Underwriter exercised its Over-Allotment Option to purchase 1,194,000 Option Shares and 1,732,500 Option Warrants at the same price per share and accompanying warrant as in the Offering, which 1,732,500 Option Warrants are exercisable for up to 83,580 shares. The foregoing description of the terms of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Amendment No. 1 to Underwriting Agreement, dated November 7, 2025, by and between VolitionRx Limited and Newbridge Securities Corporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: November 10, 2025 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 4

View Full Filing

View this 8-K/A filing on SEC EDGAR